title: PSG consensus statement on management of hepatitis C virus infection--2003.
authors.forename: S
authors.initials: S
authors.lastname: Hamid
authors.forename: M
authors.initials: M
authors.lastname: Umar
authors.forename: A
authors.initials: A
authors.lastname: Alam
authors.forename: A
authors.initials: A
authors.lastname: Siddiqui
authors.forename: H
authors.initials: H
authors.lastname: Qureshi
authors.forename: J
authors.initials: J
authors.lastname: Butt
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000209:etiology; D017063:Outcome Assessment, Health Care; D010154:Pakistan / Q000453:epidemiology; D011092:Polyethylene Glycols; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a